GH · XBRL financial data

Guardant Health financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (GH's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	143	155*	168	177	191	202*	203	232	265	281*	302	335
Revenue from contracts with customers	—	year only	168	177	191	202*	203	232	265	281*	302	335
Cost of goods and services sold	—	year only	65	72	74	78*	75	81	94	99*	105	116
Research and development	94	90*	84	83	87	94*	89	87	90	98*	91	97
General and administrative	36	38*	39	40	49	52*	47	50	53	61*	58	62
Operating income (loss)	(114)	(198)*	(100)	(101)	(117)	(126)*	(111)	(106)	(99)	(121)*	(121)	(129)
Interest income	12	14*	15	14	13	12*	9	8	7	10*	11	10
Interest expense	1	1*	1	1	1	1*	1	1	1	1*	1	1
Other income (expense)	17	(3)*	(29)	(15)	(3)	5*	8	(0)	(0)	(18)*	(0)	0
Income tax expense (benefit)	0	(1)*	0	0	0	1*	0	0	0	(2)*	0	0
Net income (loss)	(86)	(187)*	(115)	(103)	(108)	(111)*	(95)	(100)	(93)	(128)*	(112)	(120)
Earnings per share, basic USD per share	(0.73)	(1.58)*	(0.94)	(0.84)	(0.88)	(0.90)*	(0.77)	(0.80)	(0.74)	(1.00)*	(0.85)	(0.90)
Earnings per share, diluted USD per share	(0.73)	(1.58)*	(0.94)	(0.84)	(0.88)	(0.90)*	(0.77)	(0.80)	(0.74)	(1.00)*	(0.85)	(0.90)
Weighted average shares, basic millions of shares	118	119*	122	122	123	124*	124	124	125	129*	131	133
Weighted average shares, diluted millions of shares	118	119*	122	122	123	124*	124	124	125	129*	131	133

Fiscal quarters (GH's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	457	1,134	1,029	934	585	526	699	629	580	378	989	1,053
Marketable securities	697	35	0	0	311	314	0	0	0	823	113	0
Accounts receivable	89	89	85	101	88	110	115	130	116	138	137	144
Inventory	77	62	63	67	72	71	77	84	90	86	84	105
Prepaid and other current assets	26	28	32	87	67	34	36	40	43	41	43	61
Total current assets	1,347	1,347	1,309	1,290	1,227	1,055	927	883	829	1,466	1,368	1,365
Property and equipment, net	148	145	138	132	125	137	129	126	125	146	150	155
Right-of-use asset	162	158	152	146	145	142	141	170	164	159	154	148
Goodwill	3	3	3	3	3	3	3	3	3	77	77	77
Total assets	1,797	1,786	1,705	1,609	1,539	1,486	1,344	1,332	1,277	2,014	1,915	1,912
Accounts payable	78	52	38	42	15	39	50	45	20	54	75	94
Accrued liabilities	205	188	67	71	72	68	76	71	72	78	78	79
Total current liabilities	227	206	220	202	197	226	226	238	237	303	292	339
Lease liability, non-current	193	186	179	172	170	164	160	192	185	178	173	166
Total liabilities	1,569	1,628	1,636	1,611	1,599	1,625	1,595	1,637	1,631	2,113	2,096	2,135
Accumulated deficit	(1,955)	(2,142)	(2,257)	(2,359)	(2,467)	(2,578)	(2,673)	(2,773)	(2,866)	(2,995)	(3,107)	(3,227)
Total stockholders' equity	228	159	68	(2)	(60)	(140)	(251)	(305)	(354)	(99)	(181)	(223)
Total liabilities and equity	1,797	1,786	1,705	1,609	1,539	1,486	1,344	1,332	1,277	2,014	1,915	1,912
Common shares outstanding (cover page) millions of shares	118	122	122	123	124	123	124	125	126	131	133	134

Fiscal quarters (GH's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(86)	(187)*	(115)	(103)	(108)	(111)*	(95)	(100)	(93)	(128)*	(112)	(120)
Stock-based compensation	22*	24*	27	27*	50*	36*	38	42*	43*	43*	48	58*
Depreciation and amortization	11*	11*	11	11*	11*	10*	10	10*	9*	10*	9	10*
Net cash from operating activities	(78)*	(79)*	(30)	(94)*	(51)*	(65)*	(63)	(60)*	(35)*	(26)*	(66)	(58)*
Purchases of property and equipment	2*	4*	7	5*	4*	19*	4	6*	10*	28*	6	12*
Net cash from investing activities	261*	663*	28	(5)*	(295)*	11*	303	(11)*	(14)*	(905)*	699	101*
Proceeds from issuing common stock	0*	91*	—	—	0*	0*	—	—	—	year only	—	—
Share repurchases	—	year only	0	0*	0*	0*	45	0*	0*	0*	0	0*
Net cash from financing activities	4*	91*	(1)	6*	(3)*	(3)*	(67)	2*	4*	732*	(22)	23*
Net change in cash	186*	676*	(4)	(94)*	(347)*	(59)*	174	(68)*	(46)*	(200)*	612	66*

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Guardant Health	1,053	335	(58)*	134.2M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
Lumexa Imaging Holdings	70	264	33*	96.1M	—	Q2 FY26 10-QJun 30, 2026
RadNet	726	623	94*	78.7M	—	Q2 FY26 10-QJun 30, 2026
Caris Life Sciences	not reported	264	28*	282.6M	—	Q2 FY26 10-QJun 30, 2026
Exact Sciences	956	878*	152*	190.9M	—	Q4 FY25 10-KDec 31, 2025
BillionToOne	549	109	9.1*	not reported	—	Q2 FY26 10-QJun 30, 2026
Quest Diagnostics	797	3,097	611*	110.0M	—	Q3 FY26 10-QSep 30, 2026
GRAIL	56	45	(81)*	44.7M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Labcorp Holdings	262	3,810	564*	81.2M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.